Group 1 - The company, Easy Health (02661), plans to conduct an initial public offering (IPO) from December 15 to December 18, 2025, offering a total of 26.54 million shares at a price of HKD 22.68 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - According to a report by Sullivan, the company ranks 10th in China's digital integrated health services and health insurance market based on 2024 revenue [1] - The company provides a comprehensive range of health-related services, including early disease screening, health check-ups, medical appointment services, and the sale of health products, aiming to offer affordable health solutions [1] Group 2 - The company has entered into a cornerstone investment agreement with 澳琴合鸣, which will subscribe for approximately 4.8018 million shares, totaling around RMB 100 million at the IPO price [2] - The net proceeds from the global offering are estimated to be approximately HKD 513.4 million, with 40% allocated to enhancing brand awareness and user engagement, 20% for medical and real-world research, 20% for improving AI and big data capabilities, 10% for expanding into more regions and overseas markets, and 10% for working capital and general corporate purposes [2]

Group 1 - The company, Easy Health (02661.HK), plans to globally offer 26.54 million shares, with 2.654 million shares available in Hong Kong and 23.886 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 22.68 per share, with trading expected to commence on December 23, 2025 [1] - The company ranks 10th in China's digital integrated health services and health insurance market based on revenue for 2024, and 7th in the digital health services market [1] Group 2 - The net proceeds from the global offering are estimated to be approximately HKD 513.4 million, assuming no exercise of the over-allotment option [2] - The intended use of the net proceeds includes approximately 40% for enhancing brand awareness and user engagement, 20% for medical and real-world research, 20% for improving AI and big data capabilities, 10% for expansion into more regions and overseas markets, and 10% for working capital and other general corporate purposes [2] - The company has entered into a cornerstone investment agreement with Guangdong Hengqin Yuemao Deep Cooperation Zone Aoqin Harmony Investment Partnership, agreeing to subscribe for approximately RMB 100 million worth of shares at the offering price, totaling 4.8018 million shares [1][2]

Core Insights - The conference themed "Shan Hai Ningde, Health Full Score" aims to inject strong momentum into the regional health economy by focusing on high-quality development in the health industry [1][6] Group 1: Health Industry Development - Ningde City has a diverse ecological environment and rich natural resources, making it a prime location for developing the health industry, with a forest coverage rate of 69.98% [2] - The local government has integrated the health industry into its modern industrial system, emphasizing technological innovation, talent cultivation, and ecological collaboration [2][3] - Ningde has established a "156" development system that transforms ecological advantages into industrial strengths, aiming to enhance public health and drive economic transformation [3] Group 2: Economic Contributions - Ningde ranks fourth in the province for the number of medical institution beds per capita, with 13 institutions achieving a combination of medical care and elderly care [3] - The annual output value of 17 regulated pharmaceutical enterprises exceeds 2.5 billion yuan, with specific products like Taizishen and Huangzhizi each generating over 1.5 billion yuan [3] - The massage equipment industry in Ningde has 260 enterprises with an annual output value of 22 billion yuan, showcasing the economic potential of the health sector [3] Group 3: Strategic Initiatives - The conference highlighted the release of significant documents, including the "Blue Book on Active Health Promotion and Health Management Industry Development," which reflects Ningde's commitment to standardization and innovation in the health industry [7][9] - The integration of various sectors such as medicine, manufacturing, and tourism into a cohesive health ecosystem is a strategic focus for Ningde, aligning with the "Healthy China" initiative [10] - The conference serves as a platform for technical exchange and resource integration, promoting the standardization and project cooperation within the health industry [12]

Core Viewpoint - The leading health technology platform, Qingsong Health Group, has officially passed the hearing for its IPO on the Hong Kong Stock Exchange, aiming to enhance its digital health services and insurance solutions through advanced technology [1][2] Group 1: Company Overview - Qingsong Health Group was established in 2014 and is recognized as a leading digital comprehensive health service and health insurance solution platform in China [1] - According to a report by Sullivan, Qingsong Health Group ranks seventh in China's digital health service market based on projected revenue for 2024 [1] Group 2: Service Offerings - The company provides a diverse range of personalized health services, including insurance products, health screenings, health consultations, medical appointment services, and health product sales, targeting users seeking comprehensive health solutions [1] - Qingsong Health Group leverages AI and other technologies to empower industry participants in creating high-quality health education content [1] Group 3: Technological Development - The company has developed its own AI technology stack, AIcare, which integrates artificial intelligence, big data, and cloud computing capabilities, applied across various business segments such as user services, intelligent risk control, personalized marketing, product innovation, and operational efficiency [1] - Through the continuous optimization of AIcare, Qingsong Health Group has achieved a deep and precise transformation of its health and insurance businesses, setting a new benchmark for "AI + Health" in the industry [1] Group 4: IPO Fund Utilization - The funds raised from the IPO are intended for ongoing research and development, strengthening AI technology infrastructure, expanding the digital health ecosystem, enhancing user experience, and pursuing international expansion to accelerate the realization of the long-term strategic goal of "technology empowering public health" [2]

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are set to list in Hong Kong, with two of them already listed in the US market [1][4]. Group 1: Company Summaries - **Xiaoma Zhixing** plans to issue up to 102,146,500 ordinary shares for listing on the Hong Kong Stock Exchange. The company is headquartered in Guangzhou and specializes in autonomous driving systems for taxis and trucks. As of the first half of 2025, it reported revenues of $35.43 million and a net loss of $96.09 million [1][4][5]. - **Wenyan Zhixing** intends to issue up to 102,428,200 ordinary shares for its Hong Kong listing. The company develops autonomous driving systems and software, holding licenses in seven countries. In the first half of 2025, it reported revenues of $2 billion and a net loss of $7.92 billion [1][6][5]. - **Yujian Xiaomian** aims to issue up to 235,108,000 ordinary shares for its Hong Kong listing. The company operates a chain of Chinese restaurants, primarily offering Chongqing noodles. As of April 5, 2025, it had 374 restaurants in mainland China and 6 in Hong Kong. Revenue figures from 2022 to 2024 were $418 million, $801 million, and $1.154 billion, with corresponding net profits of -$35.97 million, $45.91 million, and $60.70 million [1][8][5]. - **Qingsong Jiankang** plans to issue up to 36,496,400 ordinary shares for its Hong Kong listing. The company provides digital health services and health insurance solutions. Revenue figures from 2022 to 2025 were $394 million, $490 million, $945 million, and $656 million, with net profits of -$9.10 million, $97.17 million, $8.99 million, and $86.05 million [1][10][5]. - **Tudatong** intends to merge with TechStar Acquisition Corporation to achieve a listing on the Hong Kong Stock Exchange, issuing up to 190,240,000 ordinary shares. The company specializes in the development and production of automotive-grade lidar for advanced driving assistance systems and autonomous driving. Revenue figures from 2022 to 2024 were $66.30 million, $121 million, and $160 million, with net losses of $188 million, $219 million, and $398 million [1][11][5].

Group 1 - The China Securities Regulatory Commission has issued a notice regarding QingSong Health Corporation's plan to issue up to 36,496,400 shares for overseas listing on the Hong Kong Stock Exchange [1] - QingSong Health Corporation is a one-stop platform in China focused on providing digital integrated health services and health insurance solutions [3] - According to a report by Sullivan, QingSong Health Corporation ranks 10th in China's digital integrated health services and health insurance market based on projected revenue for 2024 [3] Group 2 - The company ranks 7th in China's digital health services market based on projected revenue for 2024 [3] - QingSong Health Corporation aims to provide accessible, precise, and affordable health solutions to those in need [3]

Core Viewpoint - Micro Medical Holdings is advancing its IPO process on the Hong Kong Stock Exchange, with a significant focus on AI medical services, which now account for 92.2% of its revenue in the first half of the year [1][3]. Financial Performance - The company has shown rapid revenue growth, with continuous operating business revenues projected to reach 1.368 billion, 1.863 billion, and 5.496 billion yuan from 2022 to 2024, reflecting a compound annual growth rate of over 100%. In the first half of this year, revenues increased by 69.4% to 3.08 billion yuan compared to the same period in 2024 [2]. - AI medical services have become the core growth engine, with revenues increasing from 628 million yuan in 2022 to 4.806 billion yuan in 2024. In the first half of this year, AI medical service revenues surged by 97.3% to 2.841 billion yuan [3]. Business Model and Services - The rapid growth in AI medical service revenue is primarily driven by the expansion of health management membership services, which generated 3.893 billion yuan in 2024, nearly a tenfold increase from 354 million yuan in 2023. In the first half of 2025, this segment further increased by 131.4% to 2.389 billion yuan [3]. - The company has developed an AI-driven value-based medical service model that enhances patient health while optimizing costs and improving the capabilities of grassroots medical institutions. This model covers the entire medical process, including pre-diagnosis, diagnosis, and post-diagnosis services [3]. AI Capabilities and Impact - Micro Medical Holdings possesses industry-leading self-developed AI medical models and applications, including AI doctors, pharmacists, health managers, and smart control systems. The company has successfully implemented these technologies in the Tianjin health community, improving cost-effectiveness and member retention [4]. - Significant improvements in disease management metrics have been observed, such as an increase in blood pressure control rates for hypertension patients from 70.04% to 79.55% and for diabetes patients from 13.71% to 23.98% between June 2024 and June 2025 [4]. Expansion and Future Plans - The AI health community model is being replicated in multiple cities, including Shanghai, Hangzhou, and Shenzhen. The operational efficiency of Micro Medical Holdings has improved, with adjusted operating loss rates narrowing from 7.0% in 2024 to 4.2% in the first half of 2025, and the company achieved positive operating cash flow for the first time [5]. - The funds raised from the IPO will primarily be used for expanding the health community in Tianjin and other regions, enhancing AI technology applications, improving medical service levels, and general corporate purposes [5].

Core Insights - The core viewpoint of the article highlights the significant growth of WeDoctor Holdings, particularly in AI medical services, which has driven overall revenue increases and positioned the company as a leader in the digital health service market in China [1] Financial Performance - In the first half of 2025, WeDoctor Holdings reported revenue of 3.08 billion yuan, representing a year-on-year growth of 69.4% [1] - AI medical service revenue reached 2.841 billion yuan, showing a substantial year-on-year increase of 97.3%, accounting for over 90% of total revenue [1] - The company's revenue from continuing operations for the years 2022, 2023, and 2024 was 1.368 billion yuan, 1.863 billion yuan, and 5.496 billion yuan respectively, with a compound annual growth rate exceeding 100% [1] Market Position - According to a report by Frost & Sullivan, WeDoctor Holdings ranks first in both the digital health service market and the AI medical health solution market in China based on 2024 revenue statistics [1]

免責聲明 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出 重大變動。 閣下閱覽本文件，即代表 閣下知悉、接納並向本公司、本公司的保薦人、整體協調人、顧 問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註冊的本公司 招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、本公司的任何保薦人、整 體協調人、顧問或包銷團成員在香港或任何其他司法權區必須進行發售活動的責任。本公司最終會 否進行發售仍屬未知 ...

Core Viewpoint - The company, Qingsong Health Group, has submitted a listing application to the Hong Kong Stock Exchange after a previous application expired, indicating a renewed effort to go public and raise capital for growth initiatives [1]. Group 1: Financial Performance - The company's projected revenues for 2022, 2023, 2024, and the first half of 2025 are approximately CNY 394 million, CNY 490 million, CNY 945 million, and CNY 656 million respectively, showing significant growth potential [1]. - Net profits are expected to fluctuate, with estimates of approximately CNY -9.1 million, CNY 97.2 million, CNY 8.99 million, and CNY 86.1 million for the same periods, indicating volatility in profitability [1]. Group 2: User Base and Services - Qingsong Health focuses on providing digital comprehensive health services and health insurance solutions, catering to users seeking holistic health solutions, including screening, health checks, medical appointments, and health product sales [2]. - The registered user numbers are projected to be around 155 million, 164 million, 168 million, and 168 million for the years 2022 to 2025, while active users are expected to decline from 71 million to 23 million over the same period [2]. Group 3: Revenue Dependence - The company relies heavily on its top five clients, with their revenue contributions being 75.4%, 71.7%, 65.6%, and 65.9% of total revenue from 2022 to the first half of 2025, and the largest client contributing 35.1%, 25.3%, 22.9%, and 25.0% respectively [3]. - The procurement from the top five suppliers accounts for 42.0%, 36.1%, 70.1%, and 77.4% of total procurement during the same periods, indicating a significant reliance on a limited number of suppliers [3]. Group 4: Fundraising Purpose - The funds raised from the IPO will primarily be used to enhance brand awareness, increase user engagement, strengthen partnerships, invest in medical and real-world research, improve AI and big data capabilities, and expand into new regions and overseas markets [2].